Actively Managed ETF Provides Investors
Targeted Exposure to Leading Life Sciences Innovations in
Biotechnology, Pharmaceuticals, and Medical Devices
Emerald Advisers, in partnership with F/m Investments, today
announces the launch of the F/m Emerald Life Sciences Innovation
ETF (LFSC), now trading on the Nasdaq Stock Market under the ticker
LFSC. This ETF offers investors exposure to the most innovative
companies in the life sciences sector, focusing on biotech,
healthcare, and medical device advancements.
“We are excited to bring this ETF to market, offering investors
access to some of the most cutting-edge developments in healthcare
and biotechnology,” shared Stacey Sears, Senior Vice President
& Portfolio Manager at Emerald. “We say “innovation starts
small,” as small-cap companies are often first-movers, particularly
in sectors like gene therapies and medical diagnostics, where they
can be nimble and groundbreaking. Emerald’s proprietary
research-driven process focuses on identifying these high-potential
firms early, leveraging our sector-specific investment team to
capture the most promising life sciences opportunities, positioning
the fund for potential long-term growth.”
The F/m Emerald Life Sciences Innovation ETF is actively
managed, focusing on small and mid-cap companies who we believe are
poised to break through in biotechnology, pharmaceuticals, and
medical technology. This sector is particularly compelling as
emerging biopharma companies accounted for two-thirds of clinical
trial starts in 2023, and 56% of new active substances approved in
2023 originated at these companies (source: IQVIA Institute). “LFSC
leverages Emerald’s proprietary 10-Step Research Process, combining
fundamental analysis with hands-on research to identify companies
that we believe are at the forefront of life sciences innovation,
where disruptive advancements push the boundaries of healthcare and
can create long-term value for shareholders by capturing early
growth opportunities,” added Emerald’s Director of Research, Joseph
W. Garner.
Speaking on LFSC, Alexander Morris, CEO of F/m Investments,
shared, "The F/m Emerald Life Sciences Innovation ETF provides an
opportunity for investors to tap into the transformative
advancements taking place in healthcare and biotech. We’re proud to
partner with Emerald to offer investors access to the dynamic
growth potential of this crucial sector and look forward to
developing additional products in the future to meet investors’
needs."
The life sciences industry is experiencing rapid growth, fueled
by an aging population, increasing healthcare demand, and
accelerated investments in biotechnology and medical innovation.
With U.S. healthcare spending in 2022 reaching $4.5 trillion,
representing 17.3% of the U.S. gross domestic product (GDP)
according to the Centers for Medicare & Medicaid Services, the
CMS Office of the Actuary projects an increase in the health
spending share of GDP to 19.7% in 2032. The F/m Emerald Life
Sciences Innovation ETF provides diversified exposure to companies
driving groundbreaking advances in healthcare, offering investors
long-term growth potential.
"Emerald has a long history of identifying high-growth
opportunities in emerging sectors. The launch of LFSC reflects our
commitment to delivering innovative investment solutions that align
with long-term growth trends,” said Scott Rehr, CEO of Emerald. “As
we explored entering the active ETF space, it was crucial to find a
partner with a proven history in ETF governance who understands the
complexities involved. That’s why we chose to partner with The RBB
Fund Complex. This partnership enables us to bring a new and
innovative ETF to market backed by both Emerald’s rigorous research
process and RBB’s operational experience.”
In conjunction with the launch of the LFSC, Emerald has released
a comprehensive white paper outlining the unprecedented growth
opportunities within the life sciences sector. The paper highlights
key trends, including how U.S. healthcare spending is projected to
reach nearly 20% of GDP by 2032 and the increasing dominance of
emerging biopharma in clinical trials and drug approvals.
About Emerald Advisers
Emerald Advisers, LLC is an asset management firm providing
research-based portfolio management. Emerald and its subsidiaries
provide growth-oriented portfolios for institutions and
individuals. Founded in 1991, Emerald provides active U.S. domestic
equity portfolio management services to institutional investors and
to individual investors via separate account management, a
collective investment trust, ETFs and the Emerald Mutual Funds.
Managing client funds since 1992, assets managed by these companies
totaled approximately $4.5 billion as of September 30, 2024.
About F/m Investments
F/m Investments is a $15 billion multi-boutique investment firm
providing diversified investment strategies to advisors and
institutional investors across asset classes, markets, and styles.
For more information, please visit www.fminvest.com.
About The RBB Fund Complex
The RBB Fund, Inc. and The RBB Fund Trust, together, are a
turnkey ETF and mutual fund solution that permits an investment
adviser to focus on asset management and distribution, while RBB
facilitates the establishment, servicing, and governance of funds.
RBB oversees approximately $30 billion in assets, supporting 12
separate investment advisers, over 20 unaffiliated sub-advisers,
and over 60 mutual fund or ETF offerings. For more information,
please visit www.rbbfund.com.
An investor should consider the investment objectives, risks,
and charges and expenses of the fund carefully before investing. A
prospectus, which contains this and other information about the
fund, may be obtained by calling 1-800-617-0004/visiting
www.emeraldetfs.com. The prospectus should be read carefully before
investing.
ETFs are subject to additional risks that do not apply to
conventional mutual funds, including the risks that the market
price of an ETF’s shares may trade at a premium or discount to its
net asset value, an active secondary trading market may not develop
or be maintained, or trading may be halted by the exchange in which
they trade, which may impact an ETF's ability to sell its shares.
Shares of any ETF are bought and sold at market price (not NAV) and
are not individually redeemed from the ETF. Brokerage commissions
will reduce returns.
The F/m Emerald Life Sciences Innovation ETF is distributed by
Quasar Distributors, LLC.
Investing involves risk. Principal loss is possible. The Fund
focuses its investments in securities of companies that are
categorized in the “life sciences” sector, including companies in
the pharmaceutical, biotechnology, health care services, and
medical device industries. Because of this, companies in the Fund's
portfolio may share common characteristics and may be more
sensitive to changes in government funding or subsidies, new or
anticipated legislative changes, or technological advances. To the
extent the Fund focuses on the health care sector, the Fund may be
more susceptible to the particular risks that may affect companies
in the health care sector than if it were invested in a wider
variety of companies in unrelated sectors. Investments in
securities of micro- and small-capitalization companies may be more
vulnerable to adverse issuer, market, political, or economic
developments than securities of larger-capitalization
companies.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241031854707/en/
Emerald Advisers, LLC 3175 Oregon Pike Leola, PA 17540
717.556.8900 800.722.4123 www.TeamEmerald.com
Media Contacts:
Emerald Matt Yemma Lyceus Group
Myemma@lyceusgroup.com 909-633-9396
F/m Investments Tucker Slosburg Lyceus Group
fmpr@lyceusgroup.com 206-635-4196
The RBB Fund Complex Rex Carlin Red Mountain Media
rex@redmtnmedia.com 206-240-5108
F/m Emerald Life Science... (NASDAQ:LFSC)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
F/m Emerald Life Science... (NASDAQ:LFSC)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
